Indications for CAFCIT ORAL SOLUTION:
Short-term treatment of apnea of prematurity in infants 28 to <33 weeks gestational age.
Maintenance: 5mg/kg caffeine citrate orally every 24 hours. Adjust based on response and serum caffeine levels.
CAFCIT ORAL SOLUTION Warnings/Precautions:
Measure baseline serum caffeine levels in infants previously treated with theophylline (or aminophylline) and in infants born to mothers who consumed caffeine prior to delivery. Serious toxicity may occur with serum caffeine levels >50mg/L. Exclude or treat other causes of apnea. Seizure disorders. Cardiovascular disease. Monitor caffeine levels in impaired renal or hepatic function; adjust dose to avoid toxicity. Monitor serum glucose levels and for necrotizing enterocolitis. Pregnancy (Cat.C).
CAFCIT ORAL SOLUTION Classification:
CAFCIT ORAL SOLUTION Interactions:
Avoid concomitant theophylline, aminophylline (increased toxicity). May be potentiated by cimetidine, ketoconazole, others (may need to reduce caffeine dose). May be antagonized by phenobarbital, phenytoin, others (may need to increase caffeine dose). Caution with CYP1A2 substrates, inhibitors, or inducers.
CNS stimulation, cardiovascular or GI effects, increased gastric aspirate, feeding intolerance, hypo- or hyperglycemia, hemorrhage, acidosis, sepsis, lung edema, dyspnea, renal effects (eg, diuresis, renal failure), necrotizing enterocolitis.
Renal. Half-life: ~3–4 days (in neonates); 5hrs (in 9 months of age).
Single-use vial (3mL)—1; Oral soln (3mL)—10